<DOC>
<DOCNO>EP-0610372</DOCNO> 
<TEXT>
<INVENTION-TITLE>
1,3-DIHYDRO-2H-IMIDAZO(4,5-B)QUINOLIN-2-ONE DERIVATIVES AS PHOSPHODIESTERASE INHIBITORS
</INVENTION-TITLE>
<CLASSIFICATIONS>C07D47100	A61K314738	C07D23396	A61K3147	A61P3700	C07D40110	C07D21500	A61K314738	C07D23340	C07D47104	A61K3147	C07D40100	C07D23372	C07D21538	C07D23376	C07D40106	C07D23300	A61P3708	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07D	A61K	C07D	A61K	A61P	C07D	C07D	A61K	C07D	C07D	A61K	C07D	C07D	C07D	C07D	C07D	C07D	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07D471	A61K31	C07D233	A61K31	A61P37	C07D401	C07D215	A61K31	C07D233	C07D471	A61K31	C07D401	C07D233	C07D215	C07D233	C07D401	C07D233	A61P37	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<DESCRIPTION>
A number of substituted imidazo[4,5-b]quinolin-2-ones are known from BE-904,671; 
DE-A-3,717,291; US-4,701,459 and US-4,943,573 as phosphodiesterase and blood 
platelet aggregation inhibitors which are useful as inotropic cardiotonics and 
antithrombotics. 
In US-A-5,043,327 which corresponds to EP-A-0,406,958, published January 9, 1991, 
there are described positive inotropic and lusitropic 3,5-dihydro-imidazo[2,1-b]quinazolin-2(1H)-one 
derivatives. The present invention is concerned with novel 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one 
derivatives having the formula 
the pharmaceutically acceptable addition salts thereof and the stereochemically isomeric 
forms thereof, wherein 
   R is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl optionally substituted with from 
1 to 3 substituents each independently selected from halo, hydroxy, C₁₋₆alkyloxy, 
C₅₋₆cycloalkyloxy, C₁₋₆alkyl or trifluoromethyl; pyridinyl; thienyl optionally substituted 
with halo or C₁₋₆alkyl; 
    C=X is a radical of formula C=O   (a), C=N―O―R¹   (b),
 
or C=CH―R²   (c);
 
   R¹ is hydrogen, tri(C₁₋₆alkyl)silyl or C₁₋₆alkyl optionally substituted with COOH, 
COOC₁₋₄alkyl, CONR³R⁴ or COOCH₂CONR⁵R⁶; 
   R² is COOH, COOC₁₋₄alkyl, CONR³R⁴, COOCH₂CONR⁵R⁶ or C₁₋₆alkyl 
optionally substituted with COOH, COOC₁₋₄alkyl, CONR³R⁴ or COOCH₂CONR⁵R⁶; 
   R³ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl, 
C₁₋₄alkyloxycarbonylC₁₋₄alkyl; 
   R⁴ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₃₋₇cycloalkyl, phenyl, thienyl or 
pyridinyl; or 
   R³ and R⁴ taken together with the nitrogen atom to which they are attached may form 
a pyrrolidinyl, morpholinyl or piperazinyl ring, said piperazinyl ring being optionally 
substituted on the nitrogen atom with C₁₋₄alkyl, (C₃₋₇cycloalkyl)C₁₋₄alkyl, phenylC₁₋₄alkyl 
or C₁₋₆alkyl substituted with one, two, three, four or five hydroxy groups; and 
   R⁵ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl, 
C₁₋₄alkyloxycarbonylC₁₋₄alkyl; 
   R⁶ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₃₋₇cycloalkyl, phenyl, thienyl or 
pyridinyl; or 
   R⁵ and R⁶ taken together with the nitrogen atom to which they are attached may form 
a pyrrolidinyl, morpholinyl or piperannyl ring, said piperazinyl ring being optionally 
substituted on the nitrogen atom with C₁₋₄alkyl, (C₃₋₇cycloalkyl)C₁₋₄alkyl, phenylC₁₋₄alkyl 
or C₁₋₆alkyl substituted with one, two, three, four or five hydroxy groups In the foregoing definitions the term halo defines fluoro, chloro,
</DESCRIPTION>
<CLAIMS>
A compound having the formula 

 
a pharmaceutically acceptable addition salt thereof or a stereochemically isomeric form 

thereof, wherein
 
   R is hydrogen, C₁₋₆alkyl, C₃₋₆cycloalkyl, phenyl optionally substituted with from 

1 to 3 substituents each independently selected from halo, hydroxy, C₁₋₆alkyloxy, 
C₅₋₆cycloalkyloxy, C₁₋₆alkyl or trifluoromethyl; pyridinyl; thienyl optionally substituted 

with halo or C₁₋₆alkyl;
 
    C=X is a radical of formula
 C=O   (a),
 C=N―O―R¹   (b),

 
or
 C=CH-R²   (c);

 
   R¹ is hydrogen, tri(C₁₋₆alkyl)silyl or C₁₋₆alkyl optionally substituted with COOH, 

COOC₁₋₄alkyl, CONR³R⁴ or COOCH₂CONR⁵R⁶;
 
   R² is COOH, COOC₁₋₄alkyl, CONR³R⁴, COOCH₂CONR⁵R⁶ or C₁₋₆alkyl 

optionally substituted with COOH, COOC₁₋₄alkyl, CONR³R⁴ or COOCH₂CONR⁵R⁶;
 
   R³ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₁₋₄alkyloxyC₁₋₄alkyl, hydroxycarbonylC₁₋₄alkyl, 

C₁-₄alkyloxycarbonylC₁₋₄alkyl;
 
   R⁴ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₃₋₇cycloalkyl, phenyl, thienyl or 

pyridinyl; or
 
   R³ and R⁴ taken together with the nitrogen atom to which they are attached may form 

a pyrrolidinyl, morpholinyl or piperazinyl ring, said piperazinyl ring being optionally 
substituted on the nitrogen atom with C₁₋₄alkyl, (C₃₋₇cycloalkyl)C₁₋₄alkyl, phenylC₁₋₄alkyl 

or C₁₋₆alkyl substituted with one, two, three, four or five hydroxy groups; and
 
   R⁵ is hydrogen, C₁-₄alkyl, hydroxyC₁₋₄alkyl C₁₋₄alkyloxyC₁₋₄alkyl, hydroxycarhonylC₁-₄alkyl, 

C₁₋₄alkyloxycarbonylC₁₋₄alkyl;
  
 

   R⁶ is hydrogen, C₁₋₄alkyl, hydroxyC₁₋₄alkyl, C₃₋₇cycloalkyl, phenyl, thienyl or 
pyridinyl; or
 
   R⁵ and R⁶ taken together with the nitrogen atom to which they are attached may form 

a pyrrolidinyl, morpholinyl or piperazinyl ring, said piperazinyl ring being optionally 
substituted on the nitrogen atom with C₁₋₄alkyl, (C₃₋₇cycloalkyl)C₁₋₄alkyl, phenylC₁₋₄alkyl 

or C₁₋₆alkyl substituted with one, two, three, four or five hydroxy groups. 
A compound according to claim 1 wherein R is hydrogen; phenyl optionally 
substituted with 1 or 2 substituents each independently selected from halo, C₁₋₆alkyloxy, 

C₅₋₆cycloalkyloxy or C₁₋₆alkyl; pyridinyl; and  C=X is a radical of formula (a) 
or (b). 
A compound according to claim 2 wherein R is hydrogen; phenyl optionally 
substituted with 1 or 2 substituents each independently selected from fluoro, chloro, 

bromo, methoxy, cyclopentyloxy or methyl; pyridinyl; and  C=X is a radical of 
formula (a) or (b), wherein R¹ is C₁₋₄alkyl optionally substituted with COOH, 

COOC₁₋₄alkyl or CONR³R⁴. 
A compound according to claim 3 wherein R is hydrogen or phenyl optionally 
substituted with 1 or 2 substituents each independently selected from fluoro, methoxy or 

methyl; and  C=X is a radical of formula (a) or (b) wherein R¹ is C₁₋₄alkyl optionally 
substituted with COOH, COOC₂H₅, CON(CH₃)(c.C₆H₁₁) or 


A compound according to claim 1 wherein the compound of formula (I) is: 
(E)-
N
-cyclohexyl-2-[[[(2,3-dihydro-2-oxo-1
H
-imidazo[4,5-b]quinolin-7-yl)phenylmethylene]
amino]oxy]
-
N
-methylacetamide;
 
7-benzoyl-1,3-dihydro-2
H
-imidazo[4,5-b]quinolin-2-one,
 
(E)-1-(cyclohexylmethyl)-4-[[[[(2,3-dihydro-2-oxo-1
H
-imidazo[4,5-b]quinolin-7-yl)methylene]
amino]oxy]
acetyl]piperazine; 

or
 
(E)-
N
-cyclohexyl-2-[[[(2,3-dihydro-2-oxo-1
H
-imidazo[4,5-b]quinolin-7-yl)methylene]
amino]oxy]
-
N
-methylacetamide. 
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and 
as active ingredient an amount of a compound as claimed in any of claims 1 to 5, said 

amount being effective in alleviating and/or curing allergic and atopic diseases.  
 
A process of preparing a pharmaceutical composition as claimed in claim 6,
characterized in that
 a therapeutically effective amount of a compound as claimed in any 
of claims 1 to 5 is intimately mixed with a pharmaceutical carrier. 
A compound as claimed in any of claims 1 to 5 for use as a medicine. 
A compound having the formula 

 
an addition salt thereof or a stereochemically isomeric form thereof, wherein R and
 
 C=X are as defined in claim 1. 
A compound having the formula 

 
an addition salt thereof or a stereochemically isomeric form thereof, wherein R and
 
 C=X are as defined in claim 1. 
A compound having the formula 

 
an addition salt thereof or a stereochemically isomeric form thereof, wherein R and
 
 C=X are as defined in claim 1.  

 
A process for preparing a compound as claimed in any of claims 1 to 5,
characterized by
a) cyclizing an intermediate of formula 

 
wherein R and  C=X are as defined in claim 1, in a solvent in the presence of an acid; 
b) cyclizing an intermediate of formula 

 
wherein R and  C=X are as defined in claim 1, in a solvent in the presence of an acid; 
c) reacting an intermediate of formula (IV), wherein R and  C=X are as defined in 
claim 1, with a reagent of formula (V), wherein W is a reactive leaving group in a 

solvent 

d) reacting a compound of formula R-C(=O)-D (I-a) wherein R is as defined in claim 
1 and -D is 


 
with a hydroxylamine derivative or an acid addition salt thereof of formula  

 
H₂N-O-R¹ (VI) wherein R¹ is as defined in claim 1, in a solvent, thus yielding a 

compound of formula R-C(=NOR¹)-D (I-b); 
e) reacting a compound of formula R-C(=O)-D (I-a) wherein R is as defined in claim 
1, with a phosphorusylide of formula (C₆H₅)₃P⁺-⁻CHR² (VII) or an ylide of 

formula (R⁷O)₂PO-⁻CHR² (VIII) wherein R⁷ represents C₁₋₆alkyl, in a reaction 
inert-solvent under an inert atmosphere, thus yielding a compound of formula 

R-C(=CHR²)-D (I-c); 
f) reacting a compound of formula R-C(=O)-D (I-a) wherein R is as defined in claim 
1, with an organometallic reagent of of formula M-CH₂-R² (XIX) wherein R² is as 

defined in claim 1 and M represents a metal group, and subsequently dehydrating 
the thus obtained alcohol of formula R-C(OH)(CH₂R²)-D (XX) by treatment with 

an acid in a solvent, thus yielding a compound of formula R-C(=CHR²)-D (I-c); 
g) 
O
-alkylating or 
O
-silylating a compound of formula R-C(=NOH)-D (I-b-2) wherein 
R is as defined in claim 1, with an alkylating or silylating reagent of formula 

R
1-a
-W¹ wherein W¹ represents a leaving group and R
1-a
 is R¹ as defined in claim 1 
but other than hydrogen, in a reaction inert solvent and in the presence of a base, 

thus yielding a compound of formula R-C(=N-OR
1-a
)-D (I-b-1); 
h) isomerizing an E- or a Z-form of a compound of formula (I-b) or a mixture thereof 
by equilibration in an acidic medium; 
i) desilylating a compound of formula R-C(=N-OR
1-a
) (I-b-1) wherein R is as 
defined in claim 1 and R
1-a
 is tri(C₁₋₆alkyl)silyl by treatment with a fluoride salt or 
hydrofluoric acid, in a solvent, thus yielding a compound of formula R-C(=NOH)-D 

(I-b-2); 
j) separating the E- and the Z-isomer of a compound of formula R-C(=N-OR
1-a
)-D 
(I-b-1) wherein R is as defined in claim 1 and R
1-a
 is tri(C₁₋₆alkyl)silyl, by selective 
crystallization or chromatography; 
k) converting the compounds of (I-b-1) and the compounds of formula (I-c) into each 
other by esterification, amidation, transesterification, transamidation and ester 

hydrolysis;  
 
l) reacting an intermediate of formula R-C(=N-W²)-D (XI) wherein R is as defined in 
claim 1 and W² represents a leaving group with a reagent HO-R
1-a
 (XII) wherein 
R
1-a
 is R¹ as defined in claim 1 but other than hydrogen, in a solvent, thus yielding 
a compound of formula R-C(=NOR
1-a
)-D (I-b-1); and
 
if further desired, converting the compounds of formula (I) into a salt form by 

treatment with a pharmaceutically acceptable acid or base; or conversely, converting 
the salt form into the free base or the free acid by treatment with alkali, respectively 

an acid; and/or preparing stereochemically isomeric forms thereof. 
</CLAIMS>
</TEXT>
</DOC>
